D. Attachment 1 - Statement of Work.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

STATEMENT OF WORK (SERVICES)

(SOW)

GENERAL INFORMATION

Title of Project:

Synthesis of tert-butyl (R)-3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate in 75 gram quantity.

Statement of Need and Purpose:

This requisition is to purchase an intermediate compound in 75 g quantity with purity >95% needed for chemistry in NCATS ETB.

Background Information and Objective:

This service is to support an ongoing DPI project, finding inhibitors of nicotinamide N-methyltransferase (NNMT) for treating ovarian cancer. This project is in collaboration with a physician scientist PI at the University of Chicago, partially supported by the NCI Chemical Biology Consortium program. The project team has identified a few lead compounds that are highly potent in the biochemical and cellular settings. The team is in need of large quantity (75 g) of a key chiral intermediate to support the synthesis of the negative control compound. The vendor will develop a chemical synthesis route for the item on a smaller scale first, and then carry out scale-up synthesis of this intermediate at the indicated scale to deliver the material in the amount of 75 g to NCATS.

Period of Performance:

Within 3 months ARO.

SCOPE OF WORK

General Requirements:

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work below:

Specific Requirements:

The contractor will make the following intermediate for NCATS.

tert-butyl (R)-3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

LEVEL OF EFFORT:

Scientist and/or technician with experience in compound/intermediate synthesis shall work on this project.

GOVERNMENT RESPONSIBILITIES

N/A

DELIVERY OR DELIVERABLES

75 g of tert-butyl (R)-3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate in powder format.

REPORTING REQUIREMENTS

The contractor will be providing reports of characterization, which will be results of LCMS and NMR to show >95% purity.

OTHER CONSIDERATIONS

Travel:

N/A Information System Security Plan:

N/A Data Rights:

N/A Section 508—Electronic and Information Technology Standards:

N/A Publications and Publicity:

N/A Confidentiality of Information:

N/A